News & Events
IMMAGENE announces seed investment round to progress novel Immuno-Oncology therapeutics
Oss, The Netherlands, November 1st, 2021 Immagene B.V. today announces it has raised a seed financing round to advance its next-generation precision Immuno-Oncology (IO) therapeutics. BOM Brabant Ventures joined as a new investor with additional support from...
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
- Expanded investor syndicate strengthens the company’s financial position and investor base ROTTERDAM, October 28, 2021 - Pan Cancer T B.V., a biotech spin-off from the Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against solid...
Swanbridge invests in Pan Cancer T
Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center - Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies - Seed investment by Swanbridge Capital and Van Herk Ventures with support from...
Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA – November 24, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive...
Swanbridge Capital invests in Immagene
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in...
Curie Capital invests in Allero Therapeutics
3 October 2019 Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform...
Allero Therapeutics secures seed investment from Swanbridge Capital
ROTTERDAM, 17 April 2019 – Swanbridge Capital, an early-stage Life Sciences venture capital fund, today announced the closing of a Seed investment in Allero Therapeutics, a biopharmaceutical company focused on the discovery and development of novel immunotherapies....
DegenRx secures funding for Alzheimer’s disease gene therapy
DegenRx secures funding for Alzheimer’s disease gene therapy
Swanbridge Capital invests in IPaDiC
Swanbridge Capital announced it invested in IPaDiC, a private company developing an implantable insulin pump for diabetes type 1 patients with an insulin resistance.
Abegaill successfully closes seed funding round
Abegaill B.V. announces the successfully closing of a seed funding round. This funding is provided by Swanbridge Capital, a Dutch life science venture capital fund, and Leander Healthcare, a Benelux medtech innovation provider.
Swanbridge Capital
Brainpark II – Building XI
Lichtenauerlaan 40
3062 ME Rotterdam
nicky@swanbridgecapital.nl